Journal
NEUROPEPTIDES
Volume 40, Issue 3, Pages 207-212Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.npep.2006.01.003
Keywords
brain phospholipase A(2); melittin; mean arterial pressure; heart rate; thromboxane A(2); intracerebroventricular
Categories
Ask authors/readers for more resources
The current study was designed to determine the cardiovascular effect of centrally administrated melittin, a phospholipase A(2) (PLA(2)) activator, and the mediation of central thromboxane A(2) (TXA(2)) and its receptors in normotensive conscious rats. Studies were performed in normotensive male Sprague Dawley rats injected intracerebroventricularly (i.c.v.) with melittin. Melittin (1.5, 3.0, 6.0 mu g/5.0 mu l; i.c.v.) caused dose- and time-dependent increases in mean arterial pressure (MAP) and decrease in heart rate (HR). Maximal effects were observed 5-10 min after 3.0 mu g dose of melittin. In order to test the mediation of central TXA(2) and its central receptors in the cardiovascular effect of melittin, the rats were pretreated with furegrelate (500.0 mu g; i.c.v.), a TXA(2) synthesis inhibitor, and SQ-29548 (8.0 mu g; i.c.v.), a TXA(2) receptor antagonist, 15 min prior to melittin (3.0 mu g). Furegrelate or SQ-29548 partially inhibited the pressor effect and bradycardia elicited by melittin. In conclusion, our findings show that centrally administered melittin increases MAP and decreases HR in conscious rats. Moreover, according to our findings, central TXA(2) and its receptors may in part mediate melittin-induced cardiovascular effects. (c) 2006 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available